干扰素联合胸腺肽治疗慢性乙型肝炎临床观察

目的 观察干扰素联合大刺量胸腺肽治疗慢性乙型肝炎抗HBV复制的临床疗效。方法 将77例HBeAg阳性、HBV-DNA阳性，随机分为治疗组54例使用干扰素联合胸腺肽治疗，对照组23例除不用胸腺肽外，干扰素用法及疗程同治疗组。结果 观察组两药联合应用后，HBeAg和HBV-DNA阴转率分别达64．8％和68．5％；对熙组上述指标阴转率分别为39．1％和43．5％，两组间HBeAg和HBV-DNA各指标间比较均有差异显著性（P〈0．05）。疗程中未见明显毒副反应。结论 干扰素联合大削量胸腺肽能提高抗乙肝病毒复制的疗效。

Clinical observation on the results in treatment of chronic hepatitis B infections with interferon and thymosin

Objective To observe the clinical anti-HBV-replication effect of IFN-a lb combined with large dose of thymopeptide on patients with chronic hepatitis B. Methods 77 patients with chronic hepatitis B whose HBeAg and HBV-DNA were positive were enrolled in this research and divided into two groups randomly:treatment group and control group.23 patients in control group were treated in the same procedure except without using thymopeptide. Results In treatment group,the negative rates of HBeAg and HBV-DNA were 64.8% and 68.5% by the and of the remedy.In control group,the percentage of the above two parameters were 39.1%and 43.5%respectively.The comparison of the three parameters between the two groups showed a significant difference(P<0.05).No obvious toxic side reactions occurred in the course of treatment. Conclusion The antiviral effect could be enhanced by IFN-a lb combined with thymopeptide.